Clinical trial · Interventional
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma
NCT01266707CI-TRIAL-00004229unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A\*2402 restricted patients with advanced hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| antiangiogenic paptide vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Vaccine
- description
- VEGRF1, VEGFR2
- interventionNames
- Biological: antiangiogenic paptide vaccine
Primary outcomes (1)
- measure
- Toxicities as assessed by NCI-CACAE ver3
- timeFrame
- 3 months
Secondary outcomes (6)
- measure
- Differences of peptide specific CTL response in vitro among sequence of peptide vaccine administration
- timeFrame
- 3 months
- measure
- CD8 population
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Unresectable or treatment-resistant patients with Hepatocellular carcinoma * Measurable disease by CT scan * ECOG performance status 0-2 * Life expectancy \> 3 months * Laboratory values as follows: 2,000/mm3 \< WBC \<15,000/mm3, Platelet counts \> 75,000/mm3, Total Bilirubin \< 1.5 mg/dl, Asparate transaminase \< 150IU/L, Alanine transaminase \< 150 IU/L, Creatinine \< 3.0mg/dl * HLA-A\*2402 * Able and willing to give valid written informed consent Exclusion Criteria: * Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception) * Brest-feeder * Active or uncontrolled infection * Steroids or immunosuppressing agent dependent status * Active or uncontrolled other malignancy * Serious or uncured wound * Decision of unsuitableness by principal investigator or physician-in charge
References
Publications (3)
- BACKGROUNDNiethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. doi: 10.1038/nm1202-794. Epub 2002 Nov 4. PMID 12415261
- BACKGROUNDIshizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9. doi: 10.1158/1078-0432.CCR-06-0750. PMID 17020992
- BACKGROUNDWada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. doi: 10.1158/0008-5472.CAN-04-3759. PMID 15930316